Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 Study of Regorafenib plus Nivolumab in Recurrent or Metastatic Solid Tumors
jRCT2031200408Phase 2Completed
- Sponsor
- Bayer
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, open-label, single-arm trial of regorafenib and nivolumab in Nonhematologic neoplasms, head and neck squamous cell carcinoma (HNSCC), Esophageal Squamous Cell Carcinoma (ESCC) and 4 more, sponsored by Bayer. Primary endpoint: Overall response rate. Started Mar 2021; status: completed.
02
Drugs
regorafenibnivolumab
03
Conditions
Nonhematologic neoplasmshead and neck squamous cell carcinoma (HNSCC)Esophageal Squamous Cell Carcinoma (ESCC)pancreatic adenocarcinoma (PDAC)biliary cancer
Beyond the preview
Go deeper on jRCT2031200408.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200408.